The latest induced, embryonic, and other pluripotent stem cell news.
Keck Medicine of USC is participating in a small Phase 1 clinical trial evaluating the safety and early effectiveness of implanting induced pluripotent stem cell-derived dopamine-producing cells into the brain for Parkinson’s...
A new kit aims to streamline 3D iPSC transfection, offering higher efficiency and lower cytotoxicity for researchers and developers.
Lineage will evaluate the new gene-edited iPSC line for immune compatibility and manufacturing potential before pursuing exclusive rights with Factor Bioscience.
The partnership aims to streamline production and quality testing of gene-edited hematopoietic stem cell therapies for HIV and rare diseases.
The new open source gene editing services are ready to help iPSC developers create off-the-shelf allogeneic cell therapies at scale.
Polyphron will use Cellino's induced pluripotent stem cells in its "autonomous tissue foundry" to reproducibly manufacture cell and tissue therapies at scale.
Researchers report that intranasal Muse cells improved motor function and reduced neurodegeneration in a Parkinson’s mouse model.
The new platforms aim to streamline large-scale production of iPSC-derived cell therapies for new indications.
OpCT-001 is an iPSC-derived cell therapy for retinitis pigmentosa, and it's now entering clinical testing following Orphan Drug status.
The new funding will support Trailhead’s efforts to commercialize iPSC-derived human cells for research and drug discovery applications.